Skip to main content
NVCT
NASDAQ Life Sciences

NXP200 Wins Breakthrough Therapy Designation in China for High-Grade Glioma

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$21.7
Mkt Cap
$687.81M
52W Low
$5.55
52W High
$29.275
52W Position info
291% above low
Off High info
26% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

NVCT has more than doubled off its 52-week low of $5.55.

Summary

Nuvectis's partner Haisco secured Breakthrough Therapy Designation from China's CDE for NXP200 in BRAF V600-mutant, recurrent or progressive high-grade glioma. This is the first regulatory milestone for NXP200 in China and validates the drug's clinical activity in a difficult-to-treat CNS tumor. The designation could expedite development and review in China, though Nuvectis's commercial rights are ex-Greater China. The company continues to advance NXP200 toward a U.S. IND submission in Q4 2026. This follows the July 2026 Chinese approval of ciprocopan (NXP100) for PNH, reinforcing the Haisco partnership's value.

Updates

  1. · Wiseek News — Early data showed responses over 40%. U.S. IND filings for NXP200 and ciprocopan are targeted for Q4.

At the time of this announcement, NVCT was trading at $21.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $687.8M. The 52-week trading range was $5.55 to $29.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

NVCT - Latest Insights

NVCT
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $19.42
Real-time Price: $20.24 info
Change: +$0.820 (+4%) info
Market Cap: $696.031M info
NVCT
Nov 04, 2026, 8:07 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $19.34
Real-time Price: $20.24 info
Change: +$0.900 (+5%) info
Market Cap: $696.031M info
NVCT
Nov 04, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.34
Real-time Price: $20.24 info
Change: +$0.900 (+5%) info
Market Cap: $696.031M info
NVCT
Oct 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $20.05
Real-time Price: $20.24 info
Change: +$0.190 (+0.95%) info
Market Cap: $696.031M info
NVCT
Aug 21, 2026, 4:37 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $23.56
Real-time Price: $20.24 info
Change: -$3.32 (-14%) info
Market Cap: $696.031M info